Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 1, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 2, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001159036-26-000047
Filed / recorded
Apr 2, 2026, 10:29 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HALOZYME THERAPEUTICS, INC.
Issuer CIK
1159036
Ticker
HALO
Reporting person
David A Ramsay
Relationship
Officer
Officer title
Interim CFO
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
Apr 1, 2026
Transaction code
A
Shares / units
10,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
10,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
This award vests in full on June 30, 2026 provided the Reporting Person remains employed through such date and is subject to a one-year holding period from the vesting date.